Thermoablation of thyroid nodules meets the patient’s standard of minimal invasiveness and is supported by the literature as an effective treatment for these nodules, which may become cancerous.

The first economic modelling of Boston Scientific Corp.’s pulsed field ablation system in U.K.’s National Health Service showed that it is more cost-effective as a treatment for paroxysmal atrial fibrillation compared to standard cryoablation.

Triastek Inc., of Nanjing, China, scored a potential $1.2 billion collaboration and platform technology license deal with Biontech SE to manufacture oral RNA therapeutics with 3D printing technology.

Tricares SAS raised $50 million in a series D financing round to support upcoming clinical trials in the U.S. and EU for its transfemoral tricuspid heart valve replacement system, Topaz.

Regulation of artificial intelligence for medical devices is still a developing space, but market competition authorities in the European Union, the U.K. and the U.S. are already examining the potential for anticompetitive behavior in this rapidly growing technological arena.

In just the second PCT filing published in the name of Newmanbrain SL, co-founders Carlos Belmonte and Joaquin Ibañez seek specific protection for the use of Newmanbrain’s functional near infrared spectroscopy system, Theia, in the diagnosis of attention deficit/hyperactivity disorder.

Swiss scientists developed hydrogel implants that could help prevent and treat endometriosis by blocking the fallopian tubes and stopping the passage of endometrial cells. The implants, though in their early stage of development, bode well for the millions of women suffering from the chronic condition.

Paige AI Inc.’s partnership with Microsoft Corp., announced last September, appears to have paid off quickly, with a study published in Nature Medicine demonstrating that their jointly developed image-based artificial intelligence model, Virchow, detects 16 cancer types as well or better than tissue-specific clinical-grade models.

A team of researchers from the University of Northumbria filed for protection of a flexible transdermal patch taht uses surface acoustic wave  technology they believe offers distinct advantages over traditional transdermal patches.

Spotlight Medical SAS recently raised €6.2 million (US$6.7 million) in seed funding to bring its first artificial intelligence-powered cancer test to the market as it looks to transform treatment of the disease. “We believe our personalized testing approach will revolutionize cancer treatment, providing everyone with the best possible chance to beat cancer,” Sylvain Berlemont, CEO of Spotlight told BioWorld.